Welcome to our dedicated page for Tg Therapeutics news (Ticker: TGTX), a resource for investors and traders seeking the latest updates and insights on Tg Therapeutics stock.
TG Therapeutics, Inc. (NASDAQ: TGTX) is a commercial-stage biopharmaceutical company focused on B-cell diseases, with news flow centered on its CD20-targeted monoclonal antibody BRIUMVI (ublituximab-xiiy) for relapsing forms of multiple sclerosis (RMS). This news page aggregates company announcements, clinical data updates, financial results, and corporate presentations related to TGTX stock.
Recent press releases highlight preliminary and reported revenue from BRIUMVI, including disclosures that product revenue consists primarily of net product sales of BRIUMVI in the United States and sales to ex-U.S. partners. Investors can follow updates on revenue guidance, operating expense targets, and commentary on how BRIUMVI commercialization influences overall company performance.
TG Therapeutics also issues frequent news about its development programs. These items include progress in the ENHANCE Phase 3b trial evaluating a simplified intravenous dosing schedule for BRIUMVI, the Phase 3 pivotal program for subcutaneous ublituximab, and the Phase 1 trial of azer-cel, an allogeneic CD19 CAR T therapy in autoimmune disease. Additional releases cover long-term ULTIMATE I & II trial data, real-world ENABLE observational study outcomes, and schedules of data presentations at neurology and multiple sclerosis congresses.
Corporate news includes participation in major healthcare and biotechnology investor conferences, rankings such as the Deloitte Technology Fast 500, and announcements of share repurchase authorizations. By following this TGTX news feed, readers can monitor how clinical results, regulatory milestones, commercialization updates, and financial disclosures intersect for TG Therapeutics and its lead therapy BRIUMVI.
TG Therapeutics (NASDAQ: TGTX) reported preliminary unaudited results and 2026 guidance on Jan 13, 2026. Full year 2025 total global revenue is approximately $616 million, with BRIUMVI U.S. net product revenue of about $182 million in Q4 and $594 million for full year 2025. For 2026 the company targets $875–900 million in total global revenue, including $825–850 million of BRIUMVI U.S. net product revenue.
2026 operating expense target is ~$350 million (ex non-cash comp) plus ~$100 million for subcutaneous BRIUMVI inventory build and secondary manufacturer start-up. Key development milestones include pivotal topline ENHANCE mid‑2026, Phase 1 azer‑cel data H2 2026, and pivotal subcutaneous BRIUMVI data year‑end 2026/1Q 2027.
TG Therapeutics (NASDAQ: TGTX) announced that Michael S. Weiss, Chairman and CEO, will present at the 44th Annual J.P. Morgan Healthcare Conference. The presentation is scheduled for Tuesday, January 13, 2026 at 1:30 PM PST. A live webcast will be available on the company’s Events page in the Investors & Media section at http://ir.tgtherapeutics.com/events, and a replay will be posted on TG’s website after the event.
TG Therapeutics (NASDAQ: TGTX) announced that Chairman and CEO Michael S. Weiss will participate in a fireside chat at the 8th Annual Evercore Healthcare Conference, taking place December 2–4, 2025.
The fireside chat is scheduled for Tuesday, December 2, 2025 at 12:30 PM ET. A live webcast will be available on the company’s Investors & Media Events page at http://ir.tgtherapeutics.com/events.
TG Therapeutics (NASDAQ: TGTX) said it ranked #27 on the 2025 Deloitte Technology Fast 500, a list of North America’s 500 fastest-growing tech and life sciences companies.
The company attributed its growth from fiscal years 2021–2024 to BRIUMVI revenues after BRIUMVI received FDA approval in December 2022 to treat adults with relapsing forms of multiple sclerosis. Management credited employee execution, continued product adoption, and patient/provider trust for the result.
TG Therapeutics (NASDAQ: TGTX) announced that Chairman and CEO Michael S. Weiss will participate in the TD Cowen Immunology & Inflammation Summit, a virtual event running November 12–13, 2025. The company said the fireside chat is scheduled for Wednesday, November 12, 2025 at 10:00 AM ET. A live webcast will be available on the company’s Investors & Media Events page at http://ir.tgtherapeutics.com/events. The presentation offers investors an opportunity to hear management commentary and participate via the live webcast.
TG Therapeutics (NASDAQ: TGTX) reported third-quarter 2025 total revenue of $161.7 million, including BRIUMVI U.S. net revenue of $152.9 million (Q3 U.S. BRIUMVI +84% YoY, +10% QoQ). The company raised full‑year 2025 guidance to ≈$600 million global revenue and ≈$585 million U.S. BRIUMVI net revenue. Management completed a $100 million share repurchase and authorized an additional $100 million program.
R&D expense was $40.9 million in Q3 and SG&A was $63.4 million. Net income benefited from a non‑recurring tax benefit of ≈$365.0 million. Cash, cash equivalents and investment securities totaled $178.3 million as of September 30, 2025. Conference call scheduled November 3, 2025 at 8:30 AM ET.
TG Therapeutics (NASDAQ:TGTX) will hold a conference call on Monday, November 3, 2025 at 8:30 AM ET to discuss third quarter 2025 financial results and provide a business outlook for the remainder of 2025.
Michael S. Weiss, Chairman and CEO, will host. The company will issue a press release with financial results prior to the call. Investors can join by phone (1-877-407-8029 U.S.; 1-201-689-8029 outside the U.S.) or listen via a live webcast on the Investors & Media Events page at www.tgtherapeutics.com. An audio replay will be available on the company website for 30 days after the call.
TG Therapeutics (NASDAQ: TGTX) announced completion of enrollment in the randomized cohort of the Phase 3 ENHANCE trial testing a consolidated Day 1/Day 15 IV dosing schedule for BRIUMVI (ublituximab) in relapsing multiple sclerosis (RMS) on Oct 28, 2025.
The trial's primary endpoint is noninferior exposure measured by AUC at Week 16. ENHANCE is randomized, double-blind and placebo-controlled and will assess pharmacokinetics, safety (including infusion-related reactions), and efficacy via T1 Gd-enhancing lesions. Dosing arms compare a single 600 mg Day 1 dose plus Day 15 placebo versus 150 mg Day 1 then 450 mg Day 15, with a 450 mg dose at Week 24.
Company commentary notes potential for a simplified regimen to improve patient convenience and infusion center efficiency and states that, if data are positive, the regimen could be ready for launch in 2027.
TG Therapeutics (NASDAQ: TGTX) announced impressive 6-year data for BRIUMVI® (ublituximab-xiiy) in treating relapsing multiple sclerosis (RMS). The data revealed that 89.9% of patients remained free from disability progression after 6 years of continuous treatment.
Key highlights include an exceptionally low annualized relapse rate of 0.012 in year 6 (equivalent to one relapse per 83 years of treatment), and 17% of continuous BRIUMVI patients achieved Confirmed Disability Improvement. The ENHANCE study demonstrated that a modified single-dose regimen was well-tolerated, while the ENABLE real-world study showed an on-treatment relapse rate of 0.015, with 99.5% of participants reporting no relapses.
TG Therapeutics (NASDAQ: TGTX) has announced three upcoming presentations featuring BRIUMVI® (ublituximab-xiiy) data for multiple sclerosis at the 2025 ECTRIMS annual meeting in Barcelona, Spain from September 24-26, 2025.
The presentations include: 1) An oral presentation on long-term efficacy and safety data from six years of the ULTIMATE I and II trials' open-label extension, 2) An ePoster on safety and tolerability from the ENHANCE study with modified dosing regimen, and 3) An ePoster presenting real-world clinical experience from the ENABLE Phase 4 observational study.
All presentations will be available on the company's website after the conference.
FAQ
What is the current stock price of Tg Therapeutics (TGTX)?
What is the market cap of Tg Therapeutics (TGTX)?
